{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:11:41Z","timestamp":1790424701303,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003191","name":"Conseil R\u00e9gional de Haute Normandie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014808","name":"Fondation Vaincre Alzheimer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007494","name":"Fondation Plan Alzheimer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007494","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA15135"],"award-info":[{"award-number":["CA15135"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejmech.2020.113059","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T21:08:49Z","timestamp":1606943329000},"page":"113059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-6920","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Toublet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0006-8625","authenticated-orcid":false,"given":"Julien","family":"Lalut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9r\u00e9nice","family":"Hatat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-7738","authenticated-orcid":false,"given":"C\u00e9dric","family":"Lecoutey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-2380","authenticated-orcid":false,"given":"Audrey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-5812","authenticated-orcid":false,"given":"Marc","family":"Since","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Corvaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-4451","authenticated-orcid":false,"given":"Thomas","family":"Freret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8120","authenticated-orcid":false,"given":"Jana","family":"Sopkov\u00e1-de Oliveira Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-5518","authenticated-orcid":false,"given":"Sylvie","family":"Claeysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-8659","authenticated-orcid":false,"given":"Michel","family":"Boulouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-2082","authenticated-orcid":false,"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113059_bib1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113059_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001191.pub2","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"15","author":"Birks","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2020.113059_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","article-title":"Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease","volume":"35","author":"Craig","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejmech.2020.113059_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/gps.935","article-title":"Cholinergic function and Alzheimer\u2019s disease","volume":"18","author":"Giacobini","year":"2003","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.113059_bib5","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer \u03b2-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2020.113059_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pneurobio.2018.12.006","article-title":"Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies","volume":"174","author":"Sharma","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2020.113059_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.drudis.2018.11.012","article-title":"Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors","volume":"24","author":"Jing","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.113059_bib8","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1021\/acs.jmedchem.9b01012","article-title":"Highly selective butyrylcholinesterase inhibitors with tunable duration of action by chemical modification of transferable carbamate units exhibit pronounced neuroprotective effect in an Alzheimer\u2019s disease mouse model","volume":"62","author":"Hoffmann","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","article-title":"Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer\u2019s disease (Review)","volume":"9","author":"Cai","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2020.113059_bib10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4155\/fmc-2017-0031","article-title":"Modulating 5-HT 4 and 5-HT 6 receptors in Alzheimer\u2019s disease treatment","volume":"9","author":"Lalut","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acschemneuro.5b00135","article-title":"Serotonin: a new hope in Alzheimer\u2019s disease?","volume":"6","author":"Claeysen","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.113059_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","article-title":"5-HT6 receptors and Alzheimer\u2019s disease","volume":"5","author":"Ram\u00edrez","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.ejmech.2020.113059_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2020.113059_bib14","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1021\/acs.jmedchem.5b00179","article-title":"Therapeutic potential of 5-HT 6 receptor agonists","volume":"58","author":"Karila","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib15","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1021\/jm5003952","article-title":"Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer\u2019s disease","volume":"57","author":"Benham\u00fa","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145710000659","article-title":"Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats","volume":"13","author":"Arnt","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2020.113059_bib17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1474-4422(14)70232-7","article-title":"Idalopirdine for Alzheimer\u2019s disease: written in the stars","volume":"13","author":"Schneider","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2020.113059_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease","volume":"319","author":"Atri","year":"2018","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2020.113059_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JAD-180595","article-title":"Open-label, multicenter, phase III extension study of Idalopirdine as adjunctive to Donepezil for the treatment of mild-moderate Alzheimer\u2019s disease","volume":"67","author":"Fr\u00f6lich","year":"2019","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2020.113059_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2017.00279","article-title":"The serotonin receptor 6 antagonist idalopirdine and acetylcholinesterase inhibitor donepezil have synergistic effects on brain activity-a functional MRI study in the awake rat","volume":"8","author":"Ferris","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113059_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib22","first-page":"1","article-title":"From combinations to multitarget-directed ligands: a continuum in Alzheimer\u2019s disease polypharmacology","author":"Albertini","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.113059_bib23","author":"Lalut"},{"key":"10.1016\/j.ejmech.2020.113059_bib24","doi-asserted-by":"crossref","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","article-title":"Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer\u2019s disease treatment","volume":"111","author":"Lecoutey","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2020.113059_bib25","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","article-title":"Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer\u2019s disease: the design of Donecopride","volume":"58","author":"Rochais","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib26","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/bph.14964","article-title":"Donecopride, a Swiss army knife with potential against Alzheimer\u2019s disease","volume":"177","author":"Rochais","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113059_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2016.08.016","article-title":"Novel multi-target-directed ligands for Alzheimer\u2019s disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation","volume":"124","author":"Wi\u0119ckowska","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2016.05.048","article-title":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer\u2019s disease","volume":"121","author":"Yahiaoui","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnagi.2019.00148","article-title":"A\u00a0novel in\u00a0vivo anti-amnesic agent, specially designed to express both acetylcholinesterase (AChE) inhibitory, serotonergic subtype 4 receptor (5-HT4R) agonist and serotonergic subtype 6 receptor (5-HT6R) inverse agonist activities, with a potential inter","volume":"11","author":"Hatat","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2020.113059_bib30","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejmech.2019.07.040","article-title":"Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands","volume":"180","author":"Rodr\u00edguez-Soacha","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib31","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/molecules24152786","article-title":"Inhibiting acetylcholinesterase to activate pleiotropic prodrugs with therapeutic interest in Alzheimer\u2019s disease","volume":"24","author":"Toublet","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.113059_bib32","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","article-title":"A\u00a0multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing","volume":"20","author":"Yogev-Falach","year":"2006","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.113059_bib33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejmech.2018.07.056","article-title":"Multi-target-directed ligands for Alzheimer\u2019s disease: discovery of chromone-based monoamine oxidase\/cholinesterase inhibitors","volume":"158","author":"Reis","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib34","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/acschemneuro.8b00391","article-title":"Reconsideration of anticholinesterase therapeutic strategies against Alzheimer\u2019s disease","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.113059_bib35","doi-asserted-by":"crossref","first-page":"10796","DOI":"10.1021\/ja9024885","article-title":"Enantioselective Bronsted acid-catalyzed N-acyliminium cyclization cascades","volume":"131","author":"Muratore","year":"2009","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113059_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113059_bib37","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm010491d","article-title":"Anticholinesterase activity of compounds related to Geneserine tautomers. N -Oxides and 1,2-Oxazines","volume":"45","author":"Yu","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib39","doi-asserted-by":"crossref","first-page":"18387","DOI":"10.1021\/acsomega.8b02121","article-title":"Dihydroquinoline carbamate DQS1-02 as a prodrug of a potent acetylcholinesterase inhibitor for Alzheimer\u2019s disease therapy: multigram-scale synthesis, mechanism investigations, in\u00a0vitro safety pharmacology, and preliminary in\u00a0vivo toxicology profile","volume":"3","author":"Alix","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2020.113059_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bioorg.2016.06.002","article-title":"Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): molecular docking and saturation transfer difference NMR (STD-NMR)","volume":"67","author":"Bacalhau","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-008-1394-2","article-title":"Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine","volume":"202","author":"Deiana","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2020.113059_bib42","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbr.2010.01.004","article-title":"WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction","volume":"208","author":"Robinson","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2020.113059_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1107\/S0108767390000277","article-title":"Phase annealing in SHELX-90: direct methods for larger structures","volume":"46","author":"Sheldrick","year":"1990","journal-title":"Acta Crystallogr. Sect. A Found. Crystallogr."},{"key":"10.1016\/j.ejmech.2020.113059_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A\u00a0short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallogr. Sect. A Found. Crystallogr."},{"key":"10.1016\/j.ejmech.2020.113059_bib45","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1021\/acs.jmedchem.5b00136","article-title":"Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top 1)\u2013Tyrosyl-DNA Phosphodiesterase I (TDP1) inhibitors","volume":"58","author":"Nguyen","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib46","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1039\/C9CC01330J","article-title":"Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer\u2019s disease","volume":"55","author":"Meden","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.113059_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-2836(95)80037-9","article-title":"Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation","volume":"245","author":"Jones","year":"1995","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.113059_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.113059_bib49","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib50","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2020.113059_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2020.113059_bib54","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/(SICI)1096-987X(19980730)19:10<1179::AID-JCC6>3.0.CO;2-J","article-title":"Temperature dependence of TIP3P, SPC, and TIP4P water from NPT Monte Carlo simulations: seeking temperatures of maximum density","volume":"19","author":"Jorgensen","year":"1998","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib55","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.ejmech.2020.113059_bib56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113059_bib57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1039\/c2md20063e","article-title":"Synthesis of dual AChE\/5-HT4 receptor multi-target directed ligands","volume":"3","author":"Lecoutey","year":"2012","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2020.113059_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbr.2012.02.012","article-title":"Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice","volume":"230","author":"Freret","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2020.113059_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF02246579","article-title":"Effects of purine analogues on spontaneous alternation in mice","volume":"123","author":"Hooper","year":"1996","journal-title":"Psychopharmacology (Berl)"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342031031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342031031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:16:05Z","timestamp":1759328165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342031031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":58,"alternative-id":["S022352342031031X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113059","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113059"}}